ストックスクリーナーアプリを入手
17.75
1.93%
-0.35
アフターアワーズ：
16.87
-0.88
-4.96%
前日終値:
$18.10
開ける：
$18.05
24時間の取引高:
863.48K
Relative Volume:
0.50
時価総額：
$1.39B
収益：
$198.84M
当期純損益:
$-111.40M
株価収益率:
-3.927
EPS:
-4.52
ネットキャッシュフロー:
$-322.28M
1週間 パフォーマンス:
-3.38%
1か月 パフォーマンス:
+16.55%
6か月 パフォーマンス:
+183.55%
1年 パフォーマンス:
+154.66%
1日の値動き範囲:
$17.32
$18.10
1週間の範囲:
$16.77
$18.90
52週間の値動き範囲:
$5.12
$19.25
Travere Therapeutics Inc Stock (TVTX) Company Profile
名前
Travere Therapeutics Inc
セクター
電話
888-969-7879
住所
3611 VALLEY CENTRE DR, SAN DIEGO
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-03-27 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-12-05 | アップグレード | Citigroup | Neutral → Buy |
| 2023-11-20 | 開始されました | Citigroup | Neutral |
| 2023-09-22 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | 再開されました | Evercore ISI | Outperform |
| 2023-07-21 | 開始されました | JP Morgan | Overweight |
| 2023-06-07 | 再開されました | Piper Sandler | Neutral |
| 2023-05-22 | 開始されました | TD Cowen | Outperform |
| 2023-05-05 | アップグレード | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | 開始されました | Guggenheim | Buy |
| 2023-02-21 | アップグレード | Wedbush | Neutral → Outperform |
| 2022-12-14 | 開始されました | Stifel | Hold |
| 2022-12-05 | 開始されました | Wells Fargo | Overweight |
| 2022-09-21 | 開始されました | Bryan Garnier | Sell |
| 2022-07-14 | 再開されました | Canaccord Genuity | Buy |
| 2022-03-31 | 開始されました | Piper Sandler | Overweight |
| 2022-02-28 | 開始されました | H.C. Wainwright | Buy |
| 2021-05-26 | ダウングレード | Wedbush | Outperform → Neutral |
すべてを表示
Travere Therapeutics Inc (TVTX) 最新ニュース
Vanguard Group Inc's Strategic Acquisition in Travere Therapeuti - GuruFocus.com
Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates - MSN
Travere Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
Travere Therapeutics, Inc. (NASDAQ:TVTX) Holdings Raised by Emerald Mutual Fund Advisers Trust - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Stock Price Expected to Rise, Scotiabank Analyst Says - Defense World
Travere Therapeutics (NASDAQ:TVTX) Stock Price Expected to Rise, Barclays Analyst Says - MarketBeat
Evercore ISI raises Travere Therapeutics target to $33 By Investing.com - Investing.com Australia
Travere Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2024 Earnings Call Transcript - Insider Monkey
Travere Therapeutics Inc (TVTX) Q3 2024 Earnings Call Highlights: Strong Sales Growth Amid Operational Challenges - GuruFocus.com
Travere Therapeutics Boosts Sales with FILSPARI Approval - TipRanks
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shares Bounce 27% But Its Business Still Trails The Industry - Simply Wall St
Travere: Q3 Earnings Snapshot - The Washington Post
Travere Therapeutics earnings beat by $1.34, revenue topped estimates - Investing.com Australia
Travere Therapeutics Inc Reports Q3 2024 Revenue of $62.9 Millio - GuruFocus.com
Travere Therapeutics Reports Third Quarter 2024 Financial Results - The Manila Times
Travere Therapeutics Inc (TVTX) Q3 2024 Earnings Report Preview: What to Expect - GuruFocus.com
TD Cowen reiterates Buy on Travere shares after PARASOL findings By Investing.com - Investing.com Canada
Semanteon Capital Management LP Purchases Shares of 36,699 Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Travere presents data reinforcing clinical benefit of FILSPARI in IgAN - Yahoo Finance
Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024 - The Manila Times
TSX Income Trust Index (RTCM) QuotePress Release - The Globe and Mail
(TVTX) Trading Report - Stock Traders Daily
Jim Cramer Says 'Hold On' To Palantir, 'Let Them Walk It - EMEA Tribune, Breaking News, World News, Latest News, Top Headlines
Travere Therapeutics (TVTX) to Release Quarterly Earnings on Thursday - MarketBeat
Jim Cramer Says 'Hold On' To Palantir, 'Let Them Walk It Up'; Warns That Travere Therapeutics Is Losing A 'Ton Of Money' - Yahoo Finance
Wall Street Analysts See a 26.27% Upside in Travere (TVTX): Can the Stock Really Move This High? - MSN
Travere Therapeutics to Report Third Quarter 2024 Financial Results - The Manila Times
Travere Therapeutics (NASDAQ:TVTX) Shares Gap UpTime to Buy? - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Upgraded at Wells Fargo & Company - MarketBeat
Travere Therapeutics Stock: A Deep Dive Into Analyst Perspectives (24 Ratings) - Benzinga
Wells Fargo raises Travere Therapeutics stock to Overweight rating By Investing.com - Investing.com Canada
State Street Corp's Strategic Reduction in Travere Therapeutics Holdings - GuruFocus.com
TVTX stock soars to 52-week high, hits $18.63 amid robust gains - Investing.com Australia
Travere Therapeutics (NASDAQ:TVTX) Hits New 1-Year HighHere's Why - MarketBeat
TVTX stock soars to 52-week high, hits $18.63 amid robust gains By Investing.com - Investing.com South Africa
Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy - StockTitan
CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy - PR Newswire
Breaking Down Travere Therapeutics: 23 Analysts Share Their Views - Benzinga
Travere Therapeutics (NASDAQ:TVTX) Earns Sector Outperform Rating from Analysts at Scotiabank - MarketBeat
Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Investing in Travere Therapeutics Inc (TVTX) Is Getting More Attractive - Knox Daily
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024 - The Manila Times
Travere Awaits FDA Ruling On Rare Kidney Disease Drug - RTTNews
Travere Therapeutics Inc (TVTX) 財務データ
収益
当期純利益
現金流量
EPS
Travere Therapeutics Inc (TVTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| LYONS GARY A | Director |
Oct 04 '24 |
Sale |
14.73 |
40,000 |
589,101 |
51,000 |
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):